Daymark Wealth Partners LLC Boosts Holdings in Becton, Dickinson and Company $BDX

Daymark Wealth Partners LLC raised its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 38.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,385 shares of the medical instruments supplier’s stock after purchasing an additional 664 shares during the period. Daymark Wealth Partners LLC’s holdings in Becton, Dickinson and Company were worth $411,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Bank of Jackson Hole Trust raised its position in shares of Becton, Dickinson and Company by 85.6% in the second quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock valued at $35,000 after buying an additional 95 shares during the last quarter. Mendel Money Management raised its position in shares of Becton, Dickinson and Company by 2.6% in the second quarter. Mendel Money Management now owns 2,254 shares of the medical instruments supplier’s stock valued at $388,000 after buying an additional 58 shares during the last quarter. Auto Owners Insurance Co raised its position in shares of Becton, Dickinson and Company by 1,224.8% in the second quarter. Auto Owners Insurance Co now owns 182,355 shares of the medical instruments supplier’s stock valued at $31,411,000 after buying an additional 168,590 shares during the last quarter. Austin Private Wealth LLC raised its position in shares of Becton, Dickinson and Company by 13.8% in the second quarter. Austin Private Wealth LLC now owns 1,528 shares of the medical instruments supplier’s stock valued at $263,000 after buying an additional 185 shares during the last quarter. Finally, New York Life Investment Management LLC raised its position in shares of Becton, Dickinson and Company by 1.6% in the second quarter. New York Life Investment Management LLC now owns 39,122 shares of the medical instruments supplier’s stock valued at $6,739,000 after buying an additional 630 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Trading Down 1.4%

NYSE BDX opened at $179.07 on Friday. The firm has a 50 day simple moving average of $188.79 and a 200-day simple moving average of $183.36. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99. The firm has a market cap of $51.33 billion, a price-to-earnings ratio of 32.21, a PEG ratio of 1.42 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.32 billion during the quarter. Equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Insider Activity at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the transaction, the director owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 1,895 shares of company stock valued at $358,995 over the last ninety days. Company insiders own 0.36% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Morgan Stanley raised their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Royal Bank Of Canada restated a “sector perform” rating and set a $211.00 price objective on shares of Becton, Dickinson and Company in a research report on Thursday, October 16th. Finally, Wells Fargo & Company raised their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research report on Friday, August 8th. Three investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $205.40.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.